• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
ACPTI study: Being positive in a negative situation is not naivety - Trimetazidine still has role in symptomatic CAD patients.ACPTI 研究：在消极情况下保持积极并非幼稚——曲美他嗪在有症状 CAD 患者中仍有作用。
Indian Heart J. 2021 Jan-Feb;73(1):135-137. doi: 10.1016/j.ihj.2020.12.013. Epub 2020 Dec 30.
2
Do we need to change the Patient Indications for Trimetazidine after ATPCI?经皮冠状动脉介入治疗（PCI）后，我们是否需要改变曲美他嗪的患者适应证？
J Assoc Physicians India. 2021 Apr;69(4):11-12.
3
A randomized, double-blind, placebo-controlled trial to assess the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI study): Rationale, design, and baseline characteristics.一项评估曲美他嗪在经皮冠状动脉介入治疗后的心绞痛患者中的疗效和安全性的随机、双盲、安慰剂对照试验（ATPCI 研究）：原理、设计和基线特征。
Am Heart J. 2019 Apr;210:98-107. doi: 10.1016/j.ahj.2018.12.015. Epub 2019 Jan 15.
4
Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial.曲美他嗪经皮冠状动脉介入治疗（ATPCI）后的疗效和安全性：一项随机、双盲、安慰剂对照试验。
Lancet. 2020 Sep 19;396(10254):830-838. doi: 10.1016/S0140-6736(20)31790-6. Epub 2020 Aug 30.
5
Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: a single-centre, prospective, randomized, double-blind study at 2-year follow-up.曲美他嗪对老年多支血管冠心病合并糖尿病患者药物洗脱支架植入术后复发性心绞痛及左心室结构的影响：一项为期 2 年随访的单中心、前瞻性、随机、双盲研究。
Clin Drug Investig. 2014 Apr;34(4):251-8. doi: 10.1007/s40261-014-0170-9.
6
Trimetazidine. A review of its use in stable angina pectoris and other coronary conditions.曲美他嗪。关于其在稳定型心绞痛及其他冠状动脉疾病中应用的综述。
Drugs. 1999 Jul;58(1):143-57. doi: 10.2165/00003495-199958010-00016.
7
Effect of trimetazidine on incidence of major adverse cardiac events in coronary artery disease patients undergoing percutaneous coronary intervention: A protocol for systematic review and meta-analysis.曲美他嗪对接受经皮冠状动脉介入治疗的冠心病患者主要不良心脏事件发生率的影响：一项系统评价和荟萃分析方案
Medicine (Baltimore). 2020 Oct 30;99(44):e22918. doi: 10.1097/MD.0000000000022918.
8
[Evaluation of the myocardial protection of trimetazidine during percutaneous coronary intervention: a multi-center randomized and controlled clinical study].[曲美他嗪在经皮冠状动脉介入治疗期间心肌保护作用的评估：一项多中心随机对照临床研究]
Zhonghua Nei Ke Za Zhi. 2010 Jun;49(6):473-6.
9
Trimetazidine in Angina Combination Therapy--the TACT study: trimetazidine versus conventional treatment in patients with stable angina pectoris in a randomized, placebo-controlled, multicenter study.曲美他嗪在心绞痛联合治疗中的应用——TACT研究：一项随机、安慰剂对照、多中心研究，比较曲美他嗪与常规治疗对稳定型心绞痛患者的疗效
Am J Ther. 2005 Jan-Feb;12(1):35-42. doi: 10.1097/00045391-200501000-00006.
10
Efficacy of trimetazidine in patients with recurrent angina: a subgroup analysis of the TRIMPOL II study.曲美他嗪在复发性心绞痛患者中的疗效：TRIMPOL II研究的亚组分析
Curr Med Res Opin. 2004 Sep;20(9):1447-54. doi: 10.1185/030079904X2637.

本文引用的文献

1
Initial Invasive or Conservative Strategy for Stable Coronary Disease.稳定型冠心病的初始侵入性或保守治疗策略。
N Engl J Med. 2020 Apr 9;382(15):1395-1407. doi: 10.1056/NEJMoa1915922. Epub 2020 Mar 30.
2
2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes.2019年欧洲心脏病学会慢性冠状动脉综合征诊断和管理指南
Eur Heart J. 2020 Jan 14;41(3):407-477. doi: 10.1093/eurheartj/ehz425.
3
Role of metabolic manipulator trimetazidine in limiting percutaneous coronary intervention-induced myocardial injury.代谢调节剂曲美他嗪在限制经皮冠状动脉介入治疗所致心肌损伤中的作用。
Indian Heart J. 2018 Dec;70 Suppl 3(Suppl 3):S365-S371. doi: 10.1016/j.ihj.2018.10.415. Epub 2018 Nov 14.
4
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.冠状动脉生物可吸收支架的盲法结局和心绞痛评估：ABSORB IV 随机试验的 30 天和 1 年结果。
Lancet. 2018 Oct 27;392(10157):1530-1540. doi: 10.1016/S0140-6736(18)32283-9. Epub 2018 Sep 25.
5
Premature coronary artery disease in India: coronary artery disease in the young (CADY) registry.印度的早发性冠状动脉疾病：青年冠状动脉疾病（CADY）登记处
Indian Heart J. 2017 Mar-Apr;69(2):211-216. doi: 10.1016/j.ihj.2016.09.009. Epub 2016 Nov 30.
6
Cardioprotective Effects of Oral Trimetazidine in Diabetic Patients With Anterior Wall Myocardial Infarction Treated with Thrombolysis.口服曲美他嗪对接受溶栓治疗的糖尿病前壁心肌梗死患者的心脏保护作用
Cardiol Res. 2014 Apr;5(2):58-67. doi: 10.14740/cr330w. Epub 2014 May 15.
7
Real-world Evidence for the Antianginal Efficacy of Trimetazidine from the Russian Observational CHOICE-2 Study.来自俄罗斯观察性CHOICE-2研究的曲美他嗪抗心绞痛疗效的真实世界证据。
Adv Ther. 2017 Apr;34(4):915-924. doi: 10.1007/s12325-017-0490-2. Epub 2017 Feb 20.
8
Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention.接受经皮冠状动脉介入治疗的患者三联抗栓治疗的持续时间与结局。
JACC Cardiovasc Interv. 2016 Jul 25;9(14):1473-83. doi: 10.1016/j.jcin.2016.04.027.
9
Stress Testing After Complete and Successful Coronary Revascularization.完全成功的冠状动脉血运重建后的应激测试。
Can J Cardiol. 2016 Aug;32(8):986.e23-9. doi: 10.1016/j.cjca.2015.12.025. Epub 2015 Dec 29.
10
Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial.经皮冠状动脉介入治疗（PCI）后不完全血运重建患者应用雷诺嗪（RIVER-PCI）：一项多中心、随机、双盲、安慰剂对照试验。
Lancet. 2016 Jan 9;387(10014):136-45. doi: 10.1016/S0140-6736(15)00459-6. Epub 2015 Oct 22.

ACPTI 研究：在消极情况下保持积极并非幼稚——曲美他嗪在有症状 CAD 患者中仍有作用。

ACPTI study: Being positive in a negative situation is not naivety - Trimetazidine still has role in symptomatic CAD patients.

机构信息

Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India.

Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India.

出版信息

Indian Heart J. 2021 Jan-Feb;73(1):135-137. doi: 10.1016/j.ihj.2020.12.013. Epub 2020 Dec 30.

DOI:10.1016/j.ihj.2020.12.013
PMID:33714401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7961246/
Abstract

of the efficAcy and safety of Trimetazidine in patients with angina pectoris having been treated by Percutaneous Coronary Intervention (ATPCI) study showed no significant difference in the incidence of primary endpoint events between trimetazidine and placebo group in angina patients who recently underwent percutaneous coronary intervention. However, the study had limitations specific to both, design and selection of patient population. Here, we present some explanations for the null effects of trimetazidine in the ATPCI study and their relevance in routine clinical practice.

摘要

关于曲美他嗪在经皮冠状动脉介入治疗（ATPCI）后心绞痛患者中的疗效和安全性的研究表明，在近期接受经皮冠状动脉介入治疗的心绞痛患者中，曲美他嗪组与安慰剂组的主要终点事件发生率无显著差异。然而，该研究存在设计和患者人群选择方面的局限性。在这里，我们对 ATPCI 研究中曲美他嗪无效的原因及其在常规临床实践中的相关性进行了一些解释。